semaglutide lawsuit in kentucky gi obstruction attorney Ozempic's double-sided coin: Amid skyrocketing popularity of GLP-1 drugs, a burgeoning looms Kentucky GLP-1 Lawyer - Bursor
Description
The potency of semaglutide was first confirmed in 2021 in The New England Journal of Medicine resulting in 14.9% weight loss compared to 2.4% placebo in 1961 subjects over 68 weeks
These medications appear to suppress hunger signals and alter the brain's response to food or other rewards
The company has been instructed to initiate a full Recall of affected products distributed through healthcare providers, pharmacies, and other channels
The SmPC notes that it can be taken at any time of day, with or without food
Any use of Rybelsus for weight loss in non-diabetic individuals would be "off-label" and must be carefully managed by a doctor, considering the cost and side effects
doi: 10.1002/alz.12362 [DOI] [PMC free article] [PubMed] [Google Scholar] 117
